Area of Interest: Europe
What we are looking for:
|
In European markets, we are focusing on marketed prescription products for the retail and / or hospital business as well as medical devices – in pain or in indications that target our existing customer groups. In addition, we are looking for assets in niche areas where customers can be served via a special sales force
|
|
Read our recent press releases on Grünenthal partnering projects in Europe
-
Grünenthal to acquire commercialization rights of Qutenza® in Europe from Astellas Pharma Europe
-
Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America
-
Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America
-
Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients
-
AcelRx and Grünenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
-
Grünenthal significantly strengthens its pain product portfolio in Europe
-
Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
